Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study.

ABSTRACT:

Background

Monoclonal antibodies acting on the calcitonin gene-related peptide (CGRP) or its receptor have changed migraine preventive treatment. Those treatments have led to reconsidering the outcomes of migraine prevention. Available data mostly considered benefits in terms of relative efficacy (percent or absolute decrease in monthly migraine days [MMDs] or headache days compared with baseline). However, not enough attention has been paid to residual MMDs and/or migraine-related disability in treated patients. In the present study, we aimed at comparing the relative and absolute efficacy of erenumab.

Methods

ESTEEMen was a collaborative project among 16 European headache centers which already performed real-life data collections on patients treated with erenumab for at le

SUBMITTER: Ornello R 

PROVIDER: S-EPMC8933935 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature